^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Truxima (rituximab-abbs)

    i
    Other names: CT-P10, TL011, TL 011
    Company:
    Celltrion, Indukern, Mundipharma, Nippon Kayaku, Teva
    Drug class:
    CD20 inhibitor
    Related drugs:
    4d
    BRUIN CLL-322: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (clinicaltrials.gov)
    P3, N=600, Active, not recruiting, Loxo Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs)
    16d
    Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Post-transplantation
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    19d
    NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, David Bond, MD | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1)
    |
    PD-1 expression
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs)
    26d
    Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission (clinicaltrials.gov)
    P3, N=689, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting | Trial completion date: Jan 2032 --> Jan 2027
    Enrollment closed • Trial completion date
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14) • SOX11 expression
    |
    clonoSEQ
    |
    Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)
    1m
    waveLINE-003: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (clinicaltrials.gov)
    P2/3, N=290, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2027 --> Sep 2027 | Trial primary completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Truxima (rituximab-abbs) • zilovertamab vedotin (MK-2140) • Belrapzo (bendamustine RTD)
    1m
    Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (clinicaltrialsregister.eu)
    P4, N=650, Ongoing, Isala
    New P4 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    1m
    MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Fox Chase Cancer Center | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date
    |
    Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • ondansetron intravenous
    2ms
    waveLINE-007: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Apr 2029 | Trial primary completion date: Jan 2026 --> Apr 2029
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • zilovertamab vedotin (MK-2140) • prednisolone
    2ms
    Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2024 --> Jun 2028 | Trial primary completion date: Jul 2024 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Lynparza (olaparib) • gemcitabine • Rituxan (rituximab) • Zolinza (vorinostat) • melphalan • Truxima (rituximab-abbs) • busulfan
    2ms
    Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Aug 2024 --> Jan 2025
    Trial completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs)
    2ms
    Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=3, Terminated, Academic and Community Cancer Research United | N=63 --> 3 | Trial completion date: Apr 2029 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2027 --> Mar 2024; Trial closed due to low accrual rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    3ms
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=68, Recruiting, University of Washington | Suspended --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    3ms
    NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov)
    P1, N=20, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Venclexta (venetoclax) • dasatinib • Rituxan (rituximab) • Blincyto (blinatumomab) • methotrexate • Truxima (rituximab-abbs)
    3ms
    Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, City of Hope Medical Center
    New P2 trial • Combination therapy
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • nemtabrutinib (MK-1026)
    3ms
    Pembrolizumab, Ibrutinib and Rituximab in PCNSL (clinicaltrials.gov)
    P1/2, N=37, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Aug 2024 --> Feb 2025
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    3ms
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Dec 2024
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq)
    3ms
    Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Reid Merryman, MD
    New P2 trial
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs)
    3ms
    MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Fox Chase Cancer Center
    New P2 trial
    |
    Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • ondansetron intravenous
    3ms
    Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2024 --> Aug 2025
    Trial completion date • Combination therapy • Surgery • Metastases
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    4ms
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=68, Suspended, University of Washington | N=50 --> 68
    Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    4ms
    Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P1/2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4
    Enrollment closed • Enrollment change
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    4ms
    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (clinicaltrials.gov)
    P1, N=166, Recruiting, Fate Therapeutics | N=322 --> 166
    Enrollment change • Combination therapy
    |
    cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • FT522
    4ms
    Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=113, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CCND3 (Cyclin D3)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    4ms
    A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Gottfried von Keudell, MD PhD
    New P2 trial
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    5ms
    Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (clinicaltrials.gov)
    P1, N=15, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • temozolomide • Truxima (rituximab-abbs)
    5ms
    R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, Academic and Community Cancer Research United | N=63 --> 30
    Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    carboplatin • Rituxan (rituximab) • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs)
    5ms
    NCI-2018-01100: Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia (clinicaltrials.gov)
    P1/2, N=11, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Iclusig (ponatinib) • Truxima (rituximab-abbs)
    5ms
    Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Dana-Farber Cancer Institute
    New P1 trial • Combination therapy
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • temozolomide • Truxima (rituximab-abbs)
    5ms
    RITUXERA: Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
    P4, N=134, Recruiting, Universitaire Ziekenhuizen KU Leuven | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    6ms
    An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (clinicaltrials.gov)
    P1, N=30, Recruiting, Thomas Jefferson University | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase)
    6ms
    Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=64, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jun 2024 | Trial primary completion date: May 2025 --> Jun 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    gemcitabine • Rituxan (rituximab) • clofarabine • Truxima (rituximab-abbs) • busulfan
    6ms
    NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    6ms
    Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Starasid (cytarabine ocfosfate)
    6ms
    Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=244, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • prednisolone
    6ms
    Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2025 --> Jan 2031
    Trial completion date
    |
    Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)
    6ms
    RITZ: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (clinicaltrials.gov)
    P3, N=120, Recruiting, International Extranodal Lymphoma Study Group (IELSG) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL2RA (Interleukin 2 receptor, alpha) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    MYD88 L265P • CCND1 expression • IL2RA expression
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)
    6ms
    NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • mercaptopurine • Starasid (cytarabine ocfosfate)
    6ms
    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia (clinicaltrials.gov)
    P2, N=150, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Rituxan (rituximab) • cladribine • Truxima (rituximab-abbs)
    6ms
    Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)
    6ms
    Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=64, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    gemcitabine • Rituxan (rituximab) • clofarabine • Truxima (rituximab-abbs) • busulfan
    6ms
    Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=36, Recruiting, Mehrdad Abedi, MD | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> May 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 positive
    |
    Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV
    6ms
    BRUIN CLL-322: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (clinicaltrials.gov)
    P3, N=600, Recruiting, Loxo Oncology, Inc. | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs)